CompletedNCT05257720
Evaluation of the Role of Neurodegeneration in Schizophrenia
Observational studyAges 18–65Türkiye
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Istanbul, Türkiye · TürkiyeSee all locations and recruitment
- Activities
- Study assessments
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: March 28, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 178
- Sponsor
- Istanbul Saglik Bilimleri University
- Sponsor type
- University
- Study type
- Observational
- Intervention type
- DIAGNOSTIC_TEST
- Study phase
- Not clearly listed
- Locations
- Türkiye
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05257720
- Official title
Show the full official title
Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B
Recruitment & locations
CompletedIstanbul, Türkiye · Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Istanbul Saglik Bilimleri University, a university.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics